Item 5.07 Submission of Matters to a Vote of Security Holders

The annual meeting of shareholders of Vertex Pharmaceuticals Incorporated (the "Company") was held on May 18, 2022 (the "Annual Meeting"). Set forth below are the voting results for each of the proposals submitted to a vote of the Company's shareholders at the Annual Meeting:

Proposal No. 1: Based upon the following votes, the shareholders elected Sangeeta Bhatia, Lloyd Carney, Alan Garber, Terrence Kearney, Reshma Kewalramani, Yuchun Lee, Jeffrey Leiden, Margaret McGlynn, Diana McKenzie, Bruce Sachs and Suketu "Suky" Upadhyay to serve as members of the Company's board of directors until the annual meeting of shareholders to be held in 2023:



                                  For            Against         Abstain       Non-Votes
    Sangeeta Bhatia            217,866,026        1,537,431       580,314       9,807,714
    Lloyd Carney               190,655,522       29,245,505        82,744       9,807,714
    Alan Garber                215,431,689        4,470,485        81,597       9,807,714
    Terrence Kearney           197,133,280       22,764,797        85,694       9,807,714
    Reshma Kewalramani         218,747,353        1,157,114        79,304       9,807,714
    Yuchun Lee                 215,091,147        4,791,160       101,464       9,807,714
    Jeffrey Leiden             212,867,068        7,033,947        82,756       9,807,714
    Margaret McGlynn           214,622,981        4,782,385       578,405       9,807,714
    Diana McKenzie             217,787,588        1,616,738       579,445       9,807,714
    Bruce Sachs                207,274,411       11,876,210       833,150       9,807,714
    Suketu "Suky" Upadhyay     219,273,791          610,013        99,967       9,807,714

Proposal No. 2: Based upon the following votes, the shareholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2022:



                        For            Against        Abstain       Non-Votes
                     177,775,597       51,927,015       88,873               0

Proposal No. 3: Based upon the following votes, the shareholders approved, on an advisory basis, the 2021 compensation program for the Company's named executive officers:



                       For            Against          Abstain        Non-Votes
                    202,178,849       16,105,504       1,699,418       9,807,714

Proposal No. 4: Based up the following votes, the shareholders approved the amendment and restatement of the Company's 2013 Stock and Option Plan to increase the number of shares authorized for issuance under this plan by 13.5 million shares.



                        For            Against         Abstain       Non-Votes
                     194,088,034       25,773,390       122,347       9,807,714

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses